EYENOVIA, INC. Files 8-K on Exit Costs and Other Events
Ticker: HYPD · Form: 8-K · Filed: Nov 15, 2024 · CIK: 1682639
| Field | Detail |
|---|---|
| Company | Eyenovia, INC. (HYPD) |
| Form Type | 8-K |
| Filed Date | Nov 15, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $0.2 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: restructuring, disposal, financials
TL;DR
EYENOVIA files 8-K: Exit costs, other events, and financials disclosed. Stay tuned for details.
AI Summary
On November 15, 2024, EYENOVIA, INC. filed an 8-K report detailing cost associated with exit or disposal activities. The filing also includes other events and financial statements and exhibits. The company's principal executive offices are located at 295 Madison Avenue, Suite 2400, New York, NY 10017.
Why It Matters
This filing indicates potential restructuring or divestiture activities within EYENOVIA, INC., which could impact its future operational focus and financial performance.
Risk Assessment
Risk Level: medium — Filings related to exit or disposal activities can signal significant business changes, which inherently carry a medium level of risk and uncertainty.
Key Players & Entities
- EYENOVIA, INC. (company) — Registrant
- November 15, 2024 (date) — Date of earliest event reported
- 295 Madison Avenue, Suite 2400, New York, NY 10017 (location) — Principal Executive Offices
FAQ
What specific activities are associated with the 'Cost Associated with Exit or Disposal Activities'?
The filing does not specify the exact nature of the exit or disposal activities, but it is reported under Item 2.01 and Item 7.01 of the 8-K.
Are there any material financial impacts disclosed regarding these exit or disposal activities?
The filing mentions 'Financial Statements and Exhibits' but does not provide specific dollar amounts or details on the financial impact of the exit or disposal activities in the provided text.
What are the 'Other Events' mentioned in the filing?
The filing indicates 'Other Events' are reported under Item 8.01, but the specific details of these events are not elaborated in the provided text.
When was this Form 8-K filed?
This Form 8-K was filed on November 15, 2024.
What is EYENOVIA, INC.'s primary business sector?
EYENOVIA, INC. is in the 'PHARMACEUTICAL PREPARATIONS' sector, with SIC code 2834.
Filing Stats: 608 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-11-15 16:57:18
Key Financial Figures
- $0.0001 — h registered) Common stock, par value $0.0001 per share EYEN The Nasdaq Stock Mar
- $0.2 million — relating to this reduction in force is $0.2 million. These estimated charges are subject to
Filing Documents
- tm2428238d1_8k.htm (8-K) — 26KB
- tm2428238d1_ex99-1.htm (EX-99.1) — 11KB
- image_002.jpg (GRAPHIC) — 6KB
- 0001104659-24-119760.txt ( ) — 220KB
- eyen-20241115_lab.xml (EX-101.LAB) — 33KB
- eyen-20241115_pre.xml (EX-101.PRE) — 22KB
- eyen-20241115.xsd (EX-101.SCH) — 3KB
- tm2428238d1_8k_htm.xml (XML) — 4KB
05 Costs Associated with Exit or Disposal Activities
Item 2.05 Costs Associated with Exit or Disposal Activities. The information required by this item is incorporated by reference from Item 8.01 below.
01 Other Events
Item 8.01 Other Events. On November 15, 2024, Eyenovia, Inc. (the "Company") issued a press release announcing the outcome of a review of the three-year efficacy and safety data from the MicroPine Phase 3 CHAPERONE study conducted by an independent Data Monitoring Committee. In light of the results of this review, the Company is considering a variety of steps to maximize value to all stakeholders, to reduce expenses and to evaluate its strategic options, which may include a business combination, reverse merger, asset sales or a combination of those alternatives. Further information will be made available once the evaluation of strategic options has been completed. The Company is implementing a reduction in force affecting approximately 50% of its workforce. The remaining staff will be focused on Optejet Gen-2 development, our dry eye collaborations and clobetasol commercialization. The estimated total cost of severance-related expenses relating to this reduction in force is $0.2 million. These estimated charges are subject to a number of assumptions and actual results may differ. The Company may also incur other charges not currently contemplated due to events that may occur as a result of, or associated with, the evaluation of its strategic options. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein in its entirety by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press release dated November 15, 2024. 104 Cover Page Interactive Data File (embedded within the inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EYENOVIA, INC. Dated: November 15, 2024 By: /s/ Andrew Jones Andrew Jones Chief Financial Officer